# EDGAR Filing Document

**Accession Number:** 0001846370
**File Stem:** 0001104659-25-062458
**Filing Date:** 2025-6
**Character Count:** 12102
**Document Hash:** 39c17ac6f7c8c3840ffd48c563dc040f
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-062458.hdr.sgml**: 20250625

**ACCESSION NUMBER**: 0001104659-25-062458

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20250625

**DATE AS OF CHANGE**: 20250625

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Silence Therapeutics plc
- **CENTRAL INDEX KEY:** 0001479615
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-92205
- **FILM NUMBER:** 251071555

**BUSINESS ADDRESS:**
- **STREET 1:** 72 HAMMERSMITH ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W14 8TH
- **BUSINESS PHONE:** 44-0-20-3457 6900

**MAIL ADDRESS:**
- **STREET 1:** 72 HAMMERSMITH ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W14 8TH
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Griffiths Richard Ian
- **CENTRAL INDEX KEY:** 0001846370

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** C/O SILENCE THERAPEUTICS INC.
- **STREET 2:** 72 HAMMERSMITH ROAD
- **CITY:** LONDON
- **STATE:** X0
- **ZIP:** W14 8TH

## Ex-99.A

EXHIBIT A

JOINT FILING AGREEMENT

The undersigned hereby agree that a single Schedule 13D (or any amendment thereto) relating to the Ordinary Shares of Silence Therapeutics plc shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13D.

Date: June 25, 2025

---

| | |
|:---|:---|
| **Ora Capital Limited** | **Ora Capital Limited** |
| By: | /s/ Richard Ian Griffiths |
|  | Name: Richard Ian Griffiths |
|  | Title: Director |

---

---

| |
|:---|
| **Richard Ian Griffiths** |
| /s/ Richard Ian Griffiths |

---

## Ex-99.B

**<u>Schedule 1</u>**

**<u>Transactions in ADSs Since 8 May 2025</u>**

---

| | | | | |
|:---|:---|:---|:---|:---|
| &nbsp;&nbsp;**Date** | &nbsp;&nbsp;**Nature of the<br> Transaction** | &nbsp;&nbsp;**Reporting Person** | &nbsp;&nbsp;**Amount of <br> Securities <br> Purchased/Sold** | &nbsp;&nbsp;**Price** |
| &nbsp;&nbsp;05/13/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;94234 | &nbsp;&nbsp;$4.01 |
| &nbsp;&nbsp;05/14/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;55766 | &nbsp;&nbsp;$4.07 |
| &nbsp;&nbsp;05/18/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;37023 | &nbsp;&nbsp;$4.35 |
| &nbsp;&nbsp;05/19/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;26000 | &nbsp;&nbsp;$4.87 |
| &nbsp;&nbsp;05/20/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;16000 | &nbsp;&nbsp;$4.99 |
| &nbsp;&nbsp;05/22/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;19174 | &nbsp;&nbsp;$5.04 |
| &nbsp;&nbsp;05/23/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;17187 | &nbsp;&nbsp;$4.92 |
| &nbsp;&nbsp;05/26/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;26669 | &nbsp;&nbsp;$4.91 |
| &nbsp;&nbsp;05/27/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;50000 | &nbsp;&nbsp;$5.13 |
| &nbsp;&nbsp;05/28/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;9169 | &nbsp;&nbsp;$5.11 |
| &nbsp;&nbsp;06/12/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;39305 | &nbsp;&nbsp;$5.15 |
| &nbsp;&nbsp;06/17/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;31399 | &nbsp;&nbsp;$5.29 |
| &nbsp;&nbsp;06/18/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;39049 | &nbsp;&nbsp;$5.69 |
| &nbsp;&nbsp;06/22/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;20977 | &nbsp;&nbsp;$5.84 |
| &nbsp;&nbsp;06/23/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;35005 | &nbsp;&nbsp;$5.88 |
| &nbsp;&nbsp;06/24/25 | &nbsp;&nbsp;Purchase | &nbsp;&nbsp;Richard Griffiths | &nbsp;&nbsp;26624 | &nbsp;&nbsp;$6.12 |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 9)**

**Silence Therapeutics Plc**

*(Name of Issuer)*

**Ordinary Shares, nominal value of GBP0.05 per share**

*(Title of Class of Securities)*

**G8128Y157**

*(CUSIP Number)*

**Richard Griffiths**<br>Floor 1 Liberation Station<br>Esplanade<br>St Helier Y9 JE2 3AS<br>44-1534-719761

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/25/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **G8128Y157** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Richard Ian Griffiths** | Name of reporting person<br>**Richard Ian Griffiths** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**PF** | Source of funds (See Instructions)<br>**PF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**Y9** | Citizenship or place of organization<br>**Y9** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**34543302.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**34543302.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**34543302.00** | Aggregate amount beneficially owned by each reporting person<br>**34543302.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**24.4%** | Percent of class represented by amount in Row (11)<br>**24.4%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** * Consists of (i) 19,221,525 ordinary shares represented by American Depositary Shares ("ADSs") held by Ora Capital Limited; (ii) 1,815,522 ordinary shares represented by ADSs held by Sarossa Plc; (iii) 3,967,896 ordinary shares represented by ADSs held by Cream Capital Limited; ; (iv) 300,000 ordinary shares represented by ADSs held by Blake Holdings Limited; (v) 360,000 ordinary shares represented by ADSs held by Ora Ventures Limited; (vi) 190,500 ordinary shares represented by ADSs held by Pinkey's Limited; and (vii) 8,687,859 ordinary shares represented by ADSs held by Mr. Griffiths. Each ADS represents, and at the holder's option is convertible into, three ordinary shares of the Issuer. Mr. Griffiths is a director and the controlling shareholder of each of Ora Capital Limited, Ora Ventures Limited, Blake Holdings Limited, Sarossa Plc and Cream Capital Limited and a controlling shareholder of Pinkey's Limited and possesses the power to direct the voting and disposition of these shares.
**This percentage is calculated based upon the 141,690,849 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

| **CUSIP No.** | **G8128Y157** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Ora Capital Limited** | Name of reporting person<br>**Ora Capital Limited** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**Y9** | Citizenship or place of organization<br>**Y9** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**19221525.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**19221525.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**19221525.00** | Aggregate amount beneficially owned by each reporting person<br>**19221525.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**13.6%** | Percent of class represented by amount in Row (11)<br>**13.6%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** * Consists of 19,221,525 ordinary shares represented by ADSs held by Ora Capital Limited.
**This percentage is calculated based upon the 141,690,849 outstanding ordinary shares of the Issuer, as disclosed in the Issuer's last SEC filing.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Ordinary Shares, nominal value of GBP0.05 per share

**(b) Name of Issuer:**
Silence Therapeutics Plc

**(c) Address of Issuer's Principal Executive Offices:**
72 Hammersmith Road, London, X0, W14 8TH

This Amendment No. 9 to Schedule 13D (this "Amendment"), which amends and supplements the Schedule 13D filed with the Securities and Exchange Commission (the "SEC") on June 15, 2022, as amended on July 20, 2022, October 20, 2022, August 14, 2023, March 27, 2024, December 18, 2024, March 31, 2025, April 24, 2025 and May 8, 2025 (the "Schedule 13D") on behalf of Richard Ian Griffiths, relates to the ordinary shares, nominal value GBP0.05 per share (the "Shares"), of Silence Therapeutics plc (the "Issuer"). This Amendment is being filed to reflect the open market transactions of the Issuer's ADSs by the Reporting Person together with dilution as a result of an increase in the share capital of the Issuer. Except as amended and supplemented hereby, the Schedule 13D remains in full force and effect. All capitalized terms used in this Amendment but not defined herein shall have the meanings ascribed thereto in the Schedule 13D.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

n/a

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Richard Ian Griffiths

**Signature:** /s/ Richard Ian Griffiths

**Name/Title:** Richard Ian Griffiths

**Date:** 06/25/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Ora Capital Limited

**Signature:** /s/ Richard Ian Griffiths

**Name/Title:** Director

**Date:** 06/25/2025